The Applicant has highlighted subgroups, in particular hormone receptor-positive patients, for which the absolute treatment difference (and hazard ratio) was more favourable. However, the isolation of the measured effect to hormone receptor-positive patients lacks a clear explanation, contributing to uncertainty and precluding an indication limited to this subset.